High serum fibroblast growth factor 21 levels were related to the prognosis and ventricular remodeling of heart failure patients with mildly reduced and reduced ejection fraction.

Introduction: Previous studies have shown that fibroblast growth factor 21 (FGF21) is involved in the ventricular remodeling process in heart failure with preserved ejection fraction (HFpEF). We hypothesized that high levels of FGF21 correlated with the ventricular remodeling of heart failure patients with mildly reduced (HFmrEF) and reduced ejection fraction (HFrEF).

Methods: A total of 203 participants with HFmrEF or HFrEF were enrolled and followed up from June 2018 to June 2021.

Elevated Serum Fibroblast Growth Factor 21 Is Relevant to Heart Failure Patients with Reduced Ejection Fraction.

Objective: The aim of this study was to evaluate the roles of fibroblast growth factor 21 (FGF21) in heart failure patients with reduced ejection fraction and its association with Heart Failure with reduced Ejection Fraction (HFrEF).

Methods: The level of FGF21 was measured by enzyme-linked immunosorbent assay (ELISA) in 199 subjects enrolled in this study, including 128 subjects with HFrEF and 71 control subjects. The mean follow-up time was 13.

Serum surfactant protein D is associated with the prognosis in patients with chronic kidney disease.

Background: Circulating surfactant protein D (SP-D) has been proved to be associated with cardiovascular disease and total mortality in European patients with coronary artery disease (CAD). This study was to determine whether serum SP-D levels are associated with 1-year prognosis in patients with chronic kidney disease (CKD) in a Chinese population.

Methods: Serum SP-D levels were examined by ELISA kit in 264 patients undergoing coronary angiography.